IR-arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Regulatory

December 10, 2024

Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis

Stockholm, Sweden, December 10, 2024. Affibody’s licensee ACELYRIN, INC. today announced that the Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint. Izokibep...

Regulatory

August 13, 2024

Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep

• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoint of HiSCR75 at week 12, as well as the key secondary endpoints of HiSCR90 and...

Regulatory

May 16, 2024

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 16, 2024 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Regulatory

April 19, 2024

Affibody publishes Annual Report 2023

Stockholm, Sweden, April 19, 2024. Affibody Medical AB (publ) today announced that the Annual Report for 2023 now is available at the company’s website, and as an attachment to...

Regulatory

March 26, 2024

First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, March 26, 2024. Affibody AB (“Affibody”) today announced that the first patients with gastroesophageal cancer have been dosed in a Phase 2 clinical basket study of the...

Regulatory

March 11, 2024

Affibody’s Partner ACELYRIN Announces Positive Top-line Results for Izokibep in Psoriatic Arthritis and Long-Term Clinical Benefits in Hidradenitis Suppurativa

Phase 2b/3 psoriatic arthritis clinical trial met the primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance. Robust responses were achieved for ACR70, PASI100, ACR50/PASI100,...

Regulatory

December 20, 2023

Affibody’s Licensee Rallybio Announces Preliminary Phase 1 MAD Data for RLYB116

Solna, Sweden, December 20, 2023. Affibody’s licensee Rallybio Corporation (Rallybio) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected...

Regulatory

November 27, 2023

Affibody’s Partner ACELYRIN Provides Update on Izokibep Clinical Development Program

Solna, Sweden, November 27, 2023. Affibody’s partner ACELYRIN, INC. (“ACELYRIN”) today provided an update on its izokibep clinical development program, including the ongoing global Phase 2b/3 trial in psoriatic...

Regulatory

October 3, 2023

Affibody appoints Peter Zerhouni as CFO

Solna, Sweden, October 3, 2023. Affibody AB (“Affibody”) today announced that Peter Zerhouni has been appointed Chief Financial Officer (CFO) of the Company. Peter Zerhouni joined Affibody as Chief...